COMP <GO>
MPLT vs OVID // EV/EBITDA & P/E VALUATION
MapLight Therapeutics Inc. (NASDAQ) VS. Ovid Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: MPLT 1
— OVID 3
■ METRIC PARITY
LAST: $7.72 (-3.26%) • MKT CAP: $500.1M
valuation
—
LAST: $2.56 (+4.49%) • MKT CAP: $500.0M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MPLT VS. OVID)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MPLT | OVID | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.40% | -28.50% | -3.90 | OVID | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -7.67% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 180.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 11.46 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | OVID | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 31.5 | 56.1 | -24.63 | OVID | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $500.1M | $500.0M | $89.7K | MPLT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MPLT REV | OVID REV | MPLT GROSS % | OVID GROSS % | MPLT FCF | OVID FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $7.3M | — | — | -$138.6M | -$38.3M |
| FY 2024 | $0 | $566.0K | — | — | -$79.6M | -$56.0M |
| FY 2023 | — | $392.0K | — | — | — | -$45.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MPLT // BETA —
OVID // BETA —